Long-term Prognosis After Lung Transplantation: A Monocentric Study in 510 Patients.

INTRODUCTION: Lung transplantation is the final treatment option in patients with respiratory failure. Morbidity and mortality rates associated with the management of complications is high despite advances. Postoperative complications include acute transplant rejection, bronchiolitis obliterans, and infections. Because of that, the success of this treatment option depends on the correct choice of donor and candidates to receive a transplant. OBJECTIVE: This study aims to perform a survival analysis of transplanted patients in our center and determine predictive variables of mortality. PATIENTS AND METHODS: This study is a retrospective assessment of data collected from 510 patients at the Hospital University Reina Sofía from October 1993 to December 31, 2016. Patients who were retransplanted were excluded. We collected data regarding basal characteristics of the donors and candidates to receive a transplant. We analyzed the impact in terms of future survival of basal variables from donor and donor recipients. RESULTS: Five hundred ten patients were included (average age 44 ± 17 years, 69% male), with a maximum follow-up period of 21.6 years (average follow-up 4.52 years, interquartile ratio: 0.13 to 6.97 years). Two hundred twenty-seven patients died (54.3% of the total amount). The influence of donor's basal characteristics on mortality was analyzed; moreover, the relationship between basal variables and survival were analyzed using univariate analysis. Available variables were analyzed through multivariate analysis. CONCLUSION: Lung transplantation is a treatment option with an acceptable risk of morbidity and mortality. Increased awareness of features of evolution could help to reduce postoperative complications.

Analysis of the Incidence of Noncutaneous Neoplasia After Lung Transplantation and Its Impact on Prognosis.

INTRODUCTION: Increased survival in lung transplant recipients, the need for immunosuppressive therapy, and many risk factors before and after transplantation enhance the development of malignancies. This study sought to analyze the incidence of noncutaneous tumors after lung transplantation in our hospital, the risk factors for malignancy, and its impact on prognosis. PATIENTS AND METHODS: A retrospective analysis of clinical records of patients after lung transplantation in our hospital from October 1993 to December 2014. RESULTS: The study population included 443 patients. In total, 35 neoplasia developed in 33 patients (9.6%). Twelve cases were posttransplant lymphoproliferative disorders (PTLDs), 7 localized in the native lung, 7 gynecologic neoplasia (2 in the breast, 4 in the vulva, and 1 in the cervix), 3 in the colon, 2 in the nervous system (one was an astrocytoma), 2 in the prostate, 1 in the kidney, and 1 in the esophagus. The average time between transplantation and malignancy detection was 52.7 ± 45.4 months, being earlier in patients with PTLDs than in non-PTLD. Eleven patients who developed malignancy (all patients with neoplasia in native lung and in cervix, 1 in the colon, 1 PTLD, and 1 in the nervous system) died as a result of it. The only factor associated with an increased risk of malignancy in our population was smoking history. CONCLUSIONS: Almost 10% of lung transplant recipients developed some type of noncutaneous neoplasia and the most frequently diagnosed were PTLDs. Lung neoplasia compromised most survival in these patients.

Valoración de la oxidación proteica en pacientes con apneas del sueño / Evaluation of protein oxidation in patients with sleep apnea

Introducción: en el síndrome de apneas-hipopneas del sueño (SAHS) son frecuentes los episodios de hipoxemia-reoxigenación que pueden producir sustancias oxígeno reactivas y estrés oxidativo. Pacientes y método: estudio prospectivo, con muestreo consecutivo, para determinar si la hipoxemia nocturna puede provocar oxidación proteica. Fueron incluidos pacientes con sospecha de SAHS, indicación de una polisomnografía, edad comprendida entre 25 y 49 años, y ausencia de enfermedad sistémica. Se compararon los resultados observados en un grupo clínico (IAH > 10) con los de un grupo control (IAH < 5). Resultados: se excluyeron 3 pacientes por presentar un IAH entre 5 y 10. Fueron incluidos 36 sujetos (edad = 40 ± 6,1 años, 30 hombres y 6 mujeres, IMC = 31 ± 5,9), 23 pertenecientesínas carboniladas fueron de al grupo clínico y 13 al grupo control. En el grupo clínico, los valores de prote 0,14 ± 0,179 nmol/mg y de 0,10 ±0,066 nmol/mg en el grupo control (p = 0,348). No se observó correlación significativa entre las cifras de proteínas carboniladas y el índice de apneas-hipopneas (rho = 0,197; p = 0,249), índice de de saturación >3% (rho = 0,129, p = 0,452) y porcentaje de sueño con SaO2 <90% (rho = 0,058, p = 0,736). Conclusiones: en pacientes con edad media y SAHS moderado, las proteínas carboniladas séricas se observaron más elevadas, aunque sin alcanzar diferencias significativas (AU)

Introduction: episodes of hypoxemia-reoxigenation are frequent insleep apnea-hypopnea syndrome (SAHS) and can produce reactiveoxygen substances and oxidative stress.Patients and methods: prospective study, with consecutive sampling to determine if nocturnal hypoxemia can produce oxidation. Patients with SAHS suspicion, polysomnography indication, age between 25-49 years old and without systemic disease were included. Results obtained in clinical group (IAH > 10) were comparedwith control group (IAH < 5). Resul years old, 30 men and 6 women, BMI = 31 ± 5.9), 23 patients were from clinical group and 13 from control group. In clinical group, carbonylated proteins values were 0.14 ± 0.179 nmol/mg and 0.10 ± 0.066 nmol/mg incontrol group (p = 0.348). There was not significative correlation between carbonyl proteins and apnea-hypopnea index (rho = 0.197, p = 0.249), desaturation index >3% (rho = 0.129, p = 0.452) and sleep time spent with SaO2 <90% (rho = 0.058, p = 0.736). Conclusions: in patientes with mean age and moderate SAHS, protein carbonyls were higher althout not reaching significant differences (AU)